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Long-term outcomes and predictors of iliac
angioplasty with selective stenting
Toshifumi Kudo, MD, PhD, Fiona A. Chandra, and Samuel S. Ahn, MD Los Angeles, Calif.
Objective: To review our 11-year experience of iliac angioplasty with selective stenting and to evaluate the safety, short-
and long-term patency, clinical success rates, and predictive risk factors in patients with iliac artery occlusive disease.
Methods: From August 1993 to November 2004, 151 iliac lesions (149 stenoses, 2 occlusions) in 104 patients were treated
by percutaneous transluminal angioplasty (PTA). The patients had chronic limb ischemia described as disabling
claudication (the Society for Vascular Surgery clinical category 2 or 3) in 76 (50%), rest pain (category 4) in 38 (25%), and
ulcer/gangrene (category 5) in 37 (25%). Forty-six limbs (30%) were treated with concomitant infrainguinal endovas-
cular (36, 24%) or open procedures (10, 6%). Thirty-four limbs (23%) had one or more stents placed for primary PTA
failure, including residual stenosis (>30%), mean pressure gradient (>5 mm Hg), or dissection (stent group); whereas,
117 limbs (77%) underwent PTA alone (PTA group). The affected arteries treated were 28 (19%) common iliac, 31 (20%)
external iliac, and 92 (61%) both arteries. According to TransAtlantic Inter-Society Consensus (TASC) classification, 39
limbs (26%) were in type A, 71 (47%) in type B, 36 (24%) in type C, and 5 (3%) in type D. Reporting standards of the
Society for Vascular Surgery and the International Society for Cardiovascular Surgery were followed.
Results: There was no perioperative death. Total complication rate was 0.7% (one groin hematoma). The mean follow-up
was 21 months (median, 10; range, 1 to 94 months). Only 9 (8%) of 117 of the PTA group had subsequent stent
placement for recurrent stenosis. The iliac lesions were more severe and extensive in the stent group than those in the PTA
group according to TASC classification (Mann-Whitney U test [M-W], P < .0001) and anatomic location (M-W, P 
.0019). The technical success rate was 99%, and the initial clinical success rate was 99%. Overall, the cumulative primary
patency rates at 1, 3, and 5 years were 76%, 59%, and 49% (Kaplan-Meier [K-M]). The cumulative assisted primary and
secondary patency rates at 7 years were 98% and 99% (K-M). The mean number of subsequent iliac endovascular
procedures was 1.4 per limb in patients with primary failure of iliac angioplasty/stenting. The continued clinical
improvement rates at 1, 3, and 5 years were 81%, 67%, and 53% (K-M). The limb salvage rates at 7 year were 93% (K-M).
Of 15 predictor variables studied in 151 iliac lesions, the significant independent predictors for adverse outcomes were
smoking history (P  .0074), TASC type C/type D lesions (P  .0001), and stenotic ipsilateral superficial femoral artery
(P  .0002) for the primary patency rates; chronic renal failure with hemodialysis (P  .014), ulcer/gangrene as an
indication for PTA (P < .0001), and stenotic ipsilateral superficial femoral artery (P  .034) for the continued clinical
improvement (K-M, log-rank test and Cox regression model).
Conclusions: Although the primary patency rates were not high, the assisted primary and secondary patency rates were
excellent without primary stenting. Overall, >70% of iliac lesions were treated successfully with PTA alone. The results
of this study show that selective stenting offers satisfactory assisted primary and secondary long-term patency after iliac
angioplasty. Patients with TASC type C/type D iliac lesions, a stenotic ipsilateral superficial femoral artery, ulcer/
gangrene, smoking history, and chronic renal failure with hemodialysis should be followed carefully after endovascular
iliac revascularization. These risk factors could be considered indications for primary stenting, although further studies
are needed to confirm this. ( J Vasc Surg 2005;42:466-75.)Percutaneous transluminal angioplasty (PTA) has be-
come one of the initial treatment options in patients with
iliac occlusive disease. Stents have been recommended to
correct procedural complications and improve long-term
patency. The Dutch randomized study (primary stenting vs
selective stenting) showed that selective iliac stenting is as
effective as primary stenting.1 However, many series advo-
cate routine stent placement after an otherwise uncompli-
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doi:10.1016/j.jvs.2005.05.002cated PTA (primary stenting) in an attempt to prevent
recurrent disease.2,3 Stents could prevent immediate recoil
and obstructive plaque dissection with their mechanism of
fixing the plaque against the arterial wall; however, there is
a tendency for the development of intrastent hyperplasia,
which may induce recurrent stenosis.4,5 It is still unclear
whether a stent should be inserted primarily or selectively.
The indications for iliac stenting should be defined.
The current study was undertaken to review our 11-
year experience of iliac angioplasty with selective stenting
using the same protocol and to evaluate the safety, short-
and long-term patency, clinical success rates, and predictive
risk factors in patients with iliac artery occlusive disease.
MATERIALS AND METHODS
Patient population. From August 1993 to Novem-
ber 2004, 151 consecutive primary iliac endovascular pro-
cedures in 104 patients were performed at the University of
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tients with claudication had conservative therapy for 6 to 12
months before surgical procedures. All patients were
treated with the same protocol of primary iliac angioplasty
with selective stenting. Stents were inserted only for pri-
mary PTA failure, including residual stenosis (30%),
mean pressure gradient (5 mmHg), or dissection. Con-
comitant infrainguinal procedures were performed in 46
(30%) limbs: 10 limbs (7%) had endovascular and 2 (1%)
had open procedures for claudication, and 26 (17%) had
endovascular and 8 (5%) had open procedures for critical
limb ischemia.
The records of the 151 limbs treated by angioplasty
with selective stenting were reviewed, and they form the
basis of this report. All patients had evidence of chronic
limb ischemia and were included in a retrospective cohort
study. Preoperative, intraoperative, and follow-up informa-
tion was available for all patients and was obtained from
office and hospital chart review and dictated operative
records. The study protocol was approved by the local
institutional review board.
Percutaneous transluminal angioplasty and stent
technique. Angiography and stenting were performed in
the operating room on the same day in all patients.6 Endo-
vascular procedures were performed through an ipsilateral
or contralateral femoral approach through introducer
sheaths that ranged in size from 5F to 8F. Occlusions and
stenoses were passed with a 0.035-inch hydrophilic guide
wire (Terumo Glidewire, Boston Scientific, Natick, Mass).
A bilateral femoral approach was used frequently for pa-
tients with bilateral iliac lesions. Before any intervention,
4,000 to 8,000 IU of heparin sodium was administered
systemically.
Angiographic examination and a brachiofemoral pres-
sure gradient measurement were performed before and
after the interventional procedures. Angiography was per-
formed through a pigtail catheter inside the aorta or the
ipsilateral common iliac artery with manual injection of
contrast medium (10 mL). An anteroposterior view was
taken to evaluate the lesion. If the pressure gradient was on
the borderline and the anteroposterior view did not detect
significant stenosis, an oblique (45°) view was taken and the
pressure gradient was re-evaluated with a vasodilator (pa-
paverine).
PTA was performed with standard angioplasty balloons
(4 to 8 cm in length, 6 to 10 mm in diameter) (Ultra-thin
SDS, Boston Scientific), which were selected to match the
length of the lesion and the diameter of the artery. Balloon
inflation was maintained for 60 to 120 seconds and re-
peated routinely two to four times at the same segment.
Pressure was 4 to 16 atm. If the primary angioplasty re-
sulted in residual stenosis, defined as a 30% reduction of
luminal diameter of the treated artery in comparison with
adjacent segments, or in cases of a mean brachiofemoral
pressure gradient of 5 mm Hg or both, angioplasty was
repeated with a balloon 1 mm larger than the previous. A
stent was inserted only in cases of persistent stenosis, ac-
cording to the same criteria after the repeated angioplasty.The procedure was terminated when both angiographic
and hemodynamic success had been achieved. This proto-
col was applied prospectively to all patients.
Stents were selected according to the length of the
stenosis to be treated. A balloon-expandable Palmaz stent
(Cordis Johnson & Johnson, Warren, NJ) was generally
selected. They were delivered via a long introducer sheath
(25 cm at the ipsilateral approach and 45 cm at the con-
tralateral approach). A self-expanding SMART stent (Cor-
dis, Johnson & Johnson) was selected for longer lesions,
particularly near the inguinal ligament, for the treatment of
tortuous iliac arteries and for contralateral approaches to
the treated lesion.
Patients were given aspirin before and after the proce-
dure and were continued on aspirin thereafter. Within the
most recent year of the study period, clopidogrel (Plavix,
Bristol-Myers Squibb, New York, NY) was administered to
patients who had stent placement. All patients, except one
who was discharged on the day of the procedure, were
hospitalized for 24 hours after the procedure or longer if
treatment for a complication was necessary.
Hemodynamic and radiologic evaluation.
Ankle-brachial pressure index (ABI) measurements and
duplex scans were obtained before treatment. The
Doppler ultrasound waveform was also evaluated in
those limbs with falsely elevated ankle pressures caused
by severe arterial calcification. The duplex scan of the
treated artery was ordered by the surgeon.
Patients were usually seen 2 weeks after the proce-
dure. Improvement and changes in clinical status were
determined with history and noninvasive vascular labora-
tory tests. Postoperative follow-up, consisting of a clinical
and serial duplex ultrasound examination, was conducted
every 3months during the first postoperative year and every
6 months thereafter.
Indications for repeat intervention included recurrent
symptoms, accompanied by 0.10 increase in ABI, or
recurrent stenosis60% by duplex scan. A threefold differ-
ence of the velocity across the lesion is estimated as a 60% to
80% stenosis by our institute’s vascular laboratory.
The same protocol as for the initial procedure was used
in all subsequent iliac procedures for restenoses, including
intrastent hyperplasia or occlusions: iliac stents were placed
selectively only for initial PTA failure of residual stenosis
(30%) or the brachiofemoral pressure gradient (5 mm
Hg). Thrombolysis via catheter or subintimal angioplasty,
or both, were performed for occluded lesions. All revisions
performed based on these criteria or occlusions were con-
sidered PTA or stent failure and the end of the primary
patency.7,8 Patency and limb salvage were determined at
the most recent examination.
Data analysis. The location of the lesion (common
iliac artery [CIA], external iliac artery [EIA], or both),
nature of lesions (stenosis or occlusion), TransAtlantic In-
ter-Society Consensus (TASC) lesion types,9 and status of
the ipsilateral superficial femoral artery (SFA) and profunda
femoris artery (PF) (patent or bypassed, 50% stenosis, or
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information, risk factors, and all independent variables were
statistically analyzed and correlated with outcome.
PTA or stent placement was deemed technically suc-
cessful if there was 30% residual stenosis and the bra-
chiofemoral pressure gradient was 5 mm Hg. Primary
patency was defined as a patent artery or stent without
recurrent stenosis or the need for further intervention.7
Hemodynamic success and clinical improvement (an up-
ward shift by at least one clinical category plus a change in
ABI 0.10) were defined by the Society for Vascular
Surgery (SVS) and the International Society for Cardiovas-
cular Surgery (ISCVS) reporting standards.7 All analysis
was performed according to intent-to-treat basis, including
initial technical failures.
Statistical analysis methods. P values for univariate
comparisons of categoric variables in the PTA versus stent
groups were computed by using exact 2 tests. P values for
univariate comparisons of continuous variables in the PTA
versus stent groups were computed via the Mann-Whitney
U test (M-W).
Time-to-failure curves (“survival curves”) for patency,
clinical improvement and limb salvage were computed us-
ing the Kaplan-Meier (K-M) method. Failure rates are
given as failures per 100 person-months of follow up.
Time-to-failure curves and failure rates were compared
univariately by using the log-rank test and multivariately by
using the Cox proportional hazards regression model.
Comparisons between two failure rates are also expressed
by reporting their failure rate ratio (RR).
For the primary patency and clinical improvement out-
comes, backward stepdown Cox regression using a liberal P
.15 significance criterion was used to identify the subset
of simultaneously significant factors from the pool of 15
potential predictors and to estimate failure RR. Final statis-
tical significance was defined as P .05. Results were eval-
uated and presented in accordance with the suggested
reporting standards for lower extremity surgical and percu-
Table I. Characteristics of the subjects treated with iliac a
Total
(n  104) (%)
M:F 72:32
Mean age ( SD, years) 66  10.8
Hypertension 71 (68)
Smoking 63 (61)
Coronary artery disease 62 (60)
Hyperlipidemia 55 (53)
Diabetes mellitus 50 (48)
Cerebrovascular disease 18 (17)
Chronic renal failure with hemodialysis 14 (13)
Chronic obstructive lung disease 11 (11)
PTA, Percutaneous transluminal angioplasty
*PTA group vs stent group.
†2 test.taneous procedures of the SVS/ISCS.7,8RESULTS
Demographic information. Clinical characteristics of
104 subjects and 151 iliac lesions are summarized in Tables
I and II. The mean age was 66.6 years (range, 39 to 90
years). The most commonly associated risk factors were
history of hypertension (68%), smoking (61%), coronary
artery disease (60%), hyperlipidemia (53%), and diabetes
mellitus (48%).
Indications for revascularization were disabling claudi-
cation (the SVS/ISCVS7 clinical category 2 or 3) in 76
procedures (50%) and limb salvage in 75 procedures (50%)
consisting of ischemic rest pain (category 4) in 38 (25%)
and ulcer/gangrene (category 5) in 37 (25%). The affected
limbs treated by angioplasty with or without stenting were
CIA in 28 limbs (19%), EIA in 31 limbs (20%), and both in
92 limbs (61%).
According to TASC classification, 39 limbs (26%) were
classified in type A, 71 (47%) in type B, 36 (24%) in type C,
and 5 (3%) in type D. The status of the ipsilateral SFA was
patent (including stenosis 50%, previously bypassed, and
balloon dilated) in 85 limbs (56%), 50% to 99% stenotic in
25 (17%), and occluded in 41 (27%). The status of the
ipsilateral PF was patent (including stenosis 50% and
balloon dilated) in 136 limbs (90%), 50% to 99% stenotic in
14 (9%), and occluded in one (1%).
At the primary procedures, stents were placed selec-
tively in 34 limbs (23%) (stent group), and 117 (77%) were
treated with PTA alone (PTA group). Balloon-expandable
stents were used in 29 limbs (85%), self-expanding stents in
three (9%), and a combination in two (6%). Eighteen limbs
(53%) were treated with a single stent, although 12 (35%)
had two stents, three (9%) had three stents, and one (3%)
had four stents (55 stents in total). The reasons for selective
stenting in the stent group were:
● residual stenosis (30%) in 24 limbs (70%),
● pressure gradient (5 mm Hg) without angiographic
findings of residual stenosis (30%) in three (9%),
● dissection with pressure gradient (5 mm Hg) in five
lasty with selective stenting: 104 cases
PTA group Stent group
P*(n  85) (%) (n  25) (%)
54 : 31 21:4 .053†
66.6  11.0 66.4  10.2 .99
58 (68) 17 (68) .98
48 (56) 19 (76) .079†
51 (60) 16 (64) .72
44 (52) 15 (60) .47
42 (49) 10 (40) .41
16 (19) 2 (8) .20
10 (12) 4 (16) .58
9 (11) 3 (12) .84ngiop(15%), and
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two (6%).
Univariate analysis revealed a tendency for the PTA
group to include more women than the stent group (36% vs
16%; 2, P  .053); otherwise, there was no significant
difference in age, gender, and comorbidities between the
two groups (Table I). The stent group had more both CIA
and EIA treated (M-W, P  .0019) and more severe iliac
lesions based on TSAC classification (M-W, P   .0001)
(Table II). Concomitant infrainguinal procedures were
more frequently performed in the PTA group (2, P 
.023). The status of runoff, including the ipsilateral SFA
and PF, was not significantly different between the two
groups.
Initial success and early complications. In 151 iliac
arteries, the technical success rate was 99.3% (150 of 151)
and the initial clinical success rate was 98.7% (149 of 151).
The complication rate was 0.7% (1 of 151, one groin
hematoma). There was no perioperative death. There was
no other major complication, including acute iliac artery
thrombosis, arterial rupture, acute dissection, stent infec-
tion, distal embolization, or renal failure.
Long-term success. Mean follow-up was 20.7
Table II. Characteristics of the iliac lesions in 151 limbs
Variable
Total
(n  151) (%)
Indication
Claudication 76 (50)
Rest pain 38 (25)
Ulcer/gangrene 37 (25)
Treated artery
Common iliac artery 28 (19)
External iliac artery 31 (20)
Common and external iliac
arteries
92 (61)
TASC classification
Type A 39 (26)
Type B 71 (47)
Type C 36 (24)
Type D 5 (3)
Ipsilateral SFA
Patent 85 (56)
Stenotic (50-99%) 25 (17)
Occluded 41 (27)
Ipsilateral PF
Patent 136 (90)
Stenotic (50-99%) 14 (9)
Occluded 1 (1)
Concomitant infrainguinal
procedures
Yes 46 (30)
No 105 (70)
Complication 1 (1)
Mean hospital stay ( SD, days) 1.2  0.91
PTA, Percutaneous transluminal angioplasty; TASC, TransAtlantic Inter-So
*PTA group vs stent group.
†Mann-Whitney U test.
‡2 test.months (median, 10; range, 1 to 94 months). Nineteenpatients (13%) were lost to follow up. Twelve patients
(12%) died during the follow-up, and the mortality rate was
20%  6.0% at 5 years (K-M). The primary failure was
detected at a mean of 12.7 months (range, 3 to 58 months)
after the primary procedures in the PTA group and at a
mean of 13.7 months (range, 0 to 48 months) in the stent
group (M-W, P  .35). Thirty-five limbs (23%) required
subsequent iliac procedures, with the mean number of 1.4
(range, 1 to 4) procedures per limb (Fig 1). In the PTA
group, only 9 (8%) of 117 required selective stent place-
ment subsequently for restenosis during the follow-up.
Overall, 108 (72%) of 151 were treated by angioplasty
alone. No patient required subsequent surgical reconstruc-
tion of the iliac artery.
In 151 limbs, the cumulative primary patency rates 
SE at 1, 3, and 5 years were 76% 4.4%, 59% 6.1%, and
49%  8.0% (K-M) (Fig 2). The cumulative assisted pri-
mary and secondary patency rates at 7 years were 98% 
1.1% and 99%  0.6%, respectively (K-M). The continued
clinical improvement rates  SE at 1, 3, and 5 years were
81%  3.8%, 67%  5.8%, and 53%  7.9% (K-M) (Fig 3).
The limb salvage rate at 7 years was 93  2.9% (K-M).
The outcomes were not significantly different be-
PTA group Stent group
P*(n  117) (%) (n  34) (%)
57 (49) 19 (56) .36
29 (25) 9 (26)
31 (26) 6 (18)
25 (21) 3 (9) .0019†
29 (25) 2 (6)
63 (54) 29 (85)
36 (31) 3 (9) .0001†
59 (50) 12 (35)
22 (19) 14 (41)
0 5 (15)
68 (58) 17 (50) .52
18 (15) 7 (21)
31 (27) 10 (29)
104 (89) 32 (94) .64
12 (10) 2 (6)
1 (1) 0
41 (35) 5 (15) .023‡
76 (65) 29 (85)
1 (1) 0 .44
1.3  0.91 1.2  0.91 .71
Consensus; SFA, superficial femoral artery; PF, profunda femoris artery.cietytween the PTA group and the stent group, including the
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patency rates (P  .38), secondary patency rates (P 
.59), continued clinical improvement rates (P  .71)
(Fig 5), and limb salvage rates (P  .17) (K-M, log-rank
PTA group
117 (77%)
PTA
19 (13%)
Total PTA
151 limbs 7 (5%)
Stent
1 (1%)
Stent
7 (5%)
Stent group
34 (23%)
PTA
7 (5%)
PTA
3 (2%)
Stent Stent
2 (1%) 1 (1%)
Second
subsequent
procedure
Primary
procedure
First
subsequent
procedure
Fig 1. Primary and subsequent endovascular procedure
nal angioplasty.
Fig 2. Cumulative primary, assisted primary, and secondary pa-
tency rates after iliac angioplasty with selective stenting in 151
limbs (Kaplan-Meier life table analysis).test).Univariate analysis of risk factors. Of 15 predictable
variables studied in 151 iliac lesions, the significant predic-
tors for adverse outcomes were smoking history (P 
.0074), TASC type C/type D lesions (P  .0001), and
Patent
91 (60%)
Patent
11 (7%) 108 (72%)
Patent
6 (4%)
Stent Stent
1 (1%) 1 (1%)
Patent
24 (16%)
Patent
3 (2%)
Third
subsequent
procedure
Fourth
subquent
procedure
Stent
43 (28%)
PTA alone
Overall
iliac lesions in 151 limbs. PTA, Percutaneous translumi-
Fig 3. Cumulative continued clinical improvement and limb sal-
vage rates after iliac angioplasty with selective stenting in 151 limbs
(Kaplan-Meier life table analysis). The dashed line represents a
portion of plot where the standard error (S.E.) is 10%.s forstenotic ipsilateral SFA (P .0002) for the primary patency
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hemodialysis (P  .014), ulcer/gangrene as an indication
for PTA (P  .0001), and stenotic ipsilateral SFA (P 
.034) for the continued clinical improvement (Appendix II,
online only); and ulcer/gangrene as an indication for PTA
(P  .0097) and concomitant infrainguinal procedures (P
Fig 4. Cumulative primary patency rates of the percutaneous
transluminal angioplasty (PTA) group and the stent group. There
was no significant difference between the two groups (Kaplan-
Meier, log-rank test, P .66). The dashed line represents a portion
of plot where the standard error (S.E.) is 10%.
Fig 5. Cumulative continued clinical improvement rates of the
percutaneous transluminal angioplasty (PTA) group and the stent
group. There was no significant difference between the two groups
(Kaplan-Meier, log-rank test, P .71). The dashed line represents
a portion of plot where the standard error (S.E.) is 10%. .026) for the limb salvage (K-M, log-rank test) (Appen-dix III, online only). There was a tendency that patients
with diabetes mellitus had worse continued clinical im-
provement (P  .055).
Multivariate analysis of risk factors. Cox regression
analysis revealed that smoking history (RR, 2.46; P 
.023), TASC type C/typeD lesions (RR, 6.46; P .0046),
and stenotic ipsilateral SFA (RR, 2.90; P  .0040) were
independent simultaneous predictors for the primary pa-
tency failure rates (Table III). All are associated with an
increase in patency failure. Male gender (RR, 2.51; P 
.053), age (RR, 2.78/year; P .025), chronic renal failure
with hemodialysis (RR, 3.16; P .031), ulcer/gangrene as
Table III. Multivariate analysis*: risk factors for adverse
outcomes
Variable N
Failure rate
ratio P
Primary patency/failure
Smoking
No 55 1.00
Yes 96 2.46 .023
TASC classification
Type A 39 1.00
Type B 71 3.02 .085
Type C/D 41 6.46 .0046
Ipsilateral SFA
Occluded 41 1.00
Patent† 85 1.00
Stenosis 25 2.90 .0040
Continued clinical improvement/
failure
Gender
Female 47 1.00
Male 104 2.51 .053
Age
65 65 1.00
65 or 65 86 2.78 .025
Chronic renal failure with
hemodialysis
No 133 1.00
Yes 18 3.16 .031
Indication for PTA
Claudication 76 1.00
Rest pain 38 2.45 .10
Ulcer/gangrene 37 6.28 .00020
TASC classification
Type A 39 1.00
Type B 71 1.00
Type C/D 41 3.11 .025
Ipsilateral SFA
Occluded 41 1.00
Patent† 85 1.86 .22
Stenosis 25 3.31 .023
Selected iliac stenting
No 117 3.70
Yes 34 1.00 .021
TASC, TransAtlantic Inter-Society Consensus; PTA, percutaneous translu-
minal angioplasty.
*Cox proportional hazards model. Multivariate risk (hazard) ratios are given
for each factor controlling for the other factors in the model.
†50% stenosis, previously bypassed, or balloon dilated.an indication for PTA (RR, 6.28; P  .0002), TASC type
al an
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SFA (RR, 3.31; P  .023), and PTA alone (without stent-
ing) (RR, 3.7; P  .021) were independent simultaneous
predictors for clinical failure (Table III). All are associated
with an increase in the clinical failure rate.
Stratified analysis based on TASC lesion types. At
the primary or subsequent iliac endovascular procedures,
stents were inserted selectively in 4 (10%) of 39 in TASC
type A, 16 (23%) of 71 in TASC type B, 18 (50%) of 36 in
TASC type C, and in 5 (100%) of 5 in TASC type D. Fig 6
shows the primary and subsequent procedures patients with
TASC type B and type C iliac lesions. At the primary
procedures, PTA alone was used to treat 81 limbs (76%) of
107, and 26 (24%) had selective stenting. Eight limbs (8%)
in the PTA group required subsequent stent placement for
restenosis during the follow-up. Overall, 34 (32%) iliac
lesions were treated by stenting.
DISCUSSION
Stents have shown their usefulness in improving the
early results after failed or inadequate balloon angioplasty
complicated by unstable intimal flaps and propagating sub-
intimal or medial dissection.10 Stents are now advocated for
acute dissection, residual stenosis, and residual pressure
gradient after PTA.11-15 Although the Dutch randomized
study (primary stenting vs selective stenting)1 showed
that selective iliac stenting is as effective as primary stenting,
many advocate the routine use of iliac stenting.2,3 Cur-
rently, many physicians in the United States seem to use
stents in the iliac artery more liberally, even on a routine
basis. There is little evidence to support this practice, how-
ever.
Excellent initial technical success (88% to 100%)13-17
PTA group
81 (76%)
P
Total
107 limbs
S
Stent group
26 (24%)
Primary
procedure
Fig 6. Primary and subsequent endovascular procedure
iliac lesions in 107 limbs. PTA, Percutaneous transluminand clinical success (93% to 95%)5,15,17 have been reportedin most reviews of iliac stenting. We have inserted a stent
selectively in those lesions that were considered as an initial
PTA failure, such as those with significant residual stenosis
or a significant pressure gradient, which is in agreement
with other previous papers.1,5,14,15,17-19 In our experience,
initial technical success was 99% and initial hemodynamic
success and clinical improvement was 99% in 151 arteries
with PTA with or without stenting. An initial failure of iliac
PTA was considered to be salvaged by stenting in 34 (23%)
of 151 arteries in the current study. We used the Palmaz
stent in 29 (87%) of 34 procedures. Although the various
stents currently available all give comparable results, no
comparative study to date has demonstrated any particular
stent to be superior to another.12,18,20
In the present series, the total rate of local, general, and
vascular complications was low (0.7%), and there was no
amputation nor death at 30 days, which compares favorably
with results in the literature.1,5,14,18,19,21 Iliac stenting
could be performed safely; however, its complication rates
have been reported higher than for iliac PTA alone. In the
literature, complication rates of iliac stent varied between
4% and 19.4%,5,13,14,16,18 whereas rates of 3% to 7.9% were
reported in iliac PTA series.13,21,22 Murphy,18 who used
stents routinely, reported a 1-month mortality rate of 1.2%,
although there was a 0.3% death rate in the Johnston21
series of 667 iliac PTA. In terms of complication, these data
do not favor primary stenting over PTA alone or selective
stenting.
The placement of stents as a means of improving the
long-term results after iliac PTA is debatable. Iliac stents are
generally associated with excellent results.12,23 However,
primary stenting after iliac PTA may not be justified.18
Previous documentations, including the Dutch random-
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ransAtlantic Inter-Society Consensus type B and type C
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primary stent placement vs PTA alone,24 and PTA with
selective stenting vs PTA alone.15
Intrastent hyperplasia was responsible for most of late
failures. The placement of a stent into an injured endothe-
lium or exposed collagen may increase the risk of thrombus
formation, inflammatory reaction, and periarteritis.5,18,25
Although stents may correct an immediate focal arterial
dissection after fracture of the atherosclerotic plaque, stents
may not be as effective in controlling the process of my-
ointimal hyperplasia and subsequent stenosis.4,14,25,26
Additionally, the randomized, controlled clinical
Dutch trial revealed that PTA with selective stent place-
ment was cost-effective27 and improved health-related
quality of life equally28 compared with primary stenting in
the treatment of intermittent claudication caused by an iliac
arterial stenosis. These results favor the selective insertion
of stents for more complicated iliac angioplasty procedures
rather than primary stenting.
Despite an initial technical success rate of 99% in 151
arteries, the cumulative primary patency rates at 3 and 5
years were only 59% and 49%, in our experience. They
might be considered low in comparison to previously re-
ported patency rates. These results might reflect a tabulated
outcome for all cases, analysis by intent-to-treat basis, and a
strict definition of treatment failure or complication. Al-
though two reports agreed with our results,14,16 most of
the previous documentations of selective iliac stenting were
reported with much better results of 70% to 86% at 3 years
and 69% to 75% at 5 years.5,15,17-19 However, several
caveats must be considered before these previous data can
be interpreted further. Most patients (90%) had claudica-
tion,1,5,19 many patients (76.5%) had short (3 cm) ste-
notic lesions,19 and fewer external iliac lesions were treated
compared with the current study (28% to 47% vs
72%).1,5,14,15,17-19 These variables were previously deter-
mined to be the predictors of successful balloon angioplasty
alone.29
In addition, some differences from the current study
were less strict success criterion (pressure gradient10mm
Hg),1,19 shorter-term outcomes of 24 months,1 inclu-
sion of primary stenting cases (42% to 53%),5,17 fewer
diabetic patients (11% to 29% vs 48%),1,14,15,18,19 and a
younger patient population (the mean age, 57 to 60 years
vs 67 years).1,5,17,19 The last two factors are favorable
factors reported in the previous literature.18,21,30 Thus, we
considered that it was important to review the outcome of
iliac artery angioplasty and selective stenting without the
effects of primary stenting and the highly favorable candi-
dates for surgery. The exclusion of these factors is clinically
important because it may evaluate more accurately and
appropriately the effect of selective stenting on iliac occlu-
sive disease.
In contrast to the primary patency, the assisted primary
and secondary patency rates (98% and 99% at 7 years) were
excellent in the current study. Only two iliac occlusions
occurred during follow-up. These apparently favorable re-
sults might be explained by the character of our series, theuse of stents in lesions prone to restenosis or occlusion after
PTA, and the method of follow-up. Most of the lesions
treated were stenoses; only two complete occlusions were
included in the present series.
In addition, patency was assessed by means of duplex
scanning analysis as well as symptoms and ABI measure-
ment. In our series, each time a restenosis or occlusion was
detected, the lesion was confirmed by means of angiogra-
phy with pressure gradient measurement in the surgical
room, and endovascular procedures were then performed
the same day according to the previously mentioned crite-
ria.6 Analysis of symptoms or ABI measurements alone
could not be accurate means of assessing patency.19 We
believe that careful follow-up with duplex scan could pre-
vent iliac occlusion after angioplasty with or without stent-
ing.
Based on the univariate and multivariate analyses, we
found five significant independent predictors that may ad-
versely affect the outcomes of iliac angioplasty with selec-
tive stenting: TASC type C/type D iliac lesion, stenotic
ipsilateral SFA, ulcer/gangrene, smoking history, and
chronic renal failure with hemodialysis. It would seem that
these risk factors could be considered indications for pri-
mary stenting, and it could improve the primary patency.
However, there is no proof in the literature that primary
stenting for these risk factors actually improves the primary
patency. Further studies are needed to determine whether
primary stenting for these risk factors improves the primary
patency.
TASC lesion types were statistically correlated with the
primary patency rates but not the continued clinical im-
provement. It is not known whether more severe stenosis
should be stented primarily. In addition, only a few studies
have stratified procedural features according to TASC le-
sion types.31 Becqueimin et al,19 who reported a poorer
outcome of selective stenting for stenoses 3 cm, sug-
gested that primary stenting might have improved their
results. However, in the Sullivan et al30 series of 288
patients treated with primary stenting, the lesions that
requiredmultiple stent placements were associated with the
poorest results. Other reports with more extensive and
multifocal iliac lesions described the external iliac lesion as a
significant predictor of poor outcomes.31-33
Regardless of TASC lesion types, we used the same
criteria for selective stenting for the primary lesions and
restenoses. In our experience, although all of TASC type D
lesions (5 of 5) were classified in the stent group, 76% of
TASC type B and type C lesions were successfully revascu-
larized by PTA alone at the primary procedures. Addition-
ally, in this particular group, 10% of lesions required
subsequent stent placement for restenosis during the fol-
low-up. Overall, only one-third of iliac TASC type B and
type C lesions were treated by stenting.
Our study has several limitations. First, the series is
relatively small with a short mean follow-up. Thirteen
percent were lost to follow up, and 48% (72 of 151) of
limbs were treated in the last 3 years during the study
period. When we excluded the patients who were lost to
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ued clinical improvement, and limb salvage rates at 5 years
were 49%  8.0%, 98%  1.2%, 99%  0.8%, 52%  7.9%,
and 93%  2.9%, respectively. In this subgroup of 132
patients, 94 (71%) were treated successfully by PTA alone,
whereas only 38 (29%) had stent placement during the
follow-up. These results are similar to our previously calcu-
lated results, which included the patients lost to follow-up.
Second, most of the stents used (Palmaz stent) are
somewhat outdated.
Third, the primary patency rate is lower than in many
previously published series with selective iliac stenting.
However, none of primary failures were detected during
the early phase (30 days after the primary procedures) in
PTA group. Additionally, the mean number of subsequent
iliac endovascular procedures was only 1.4 per limb.
Fourth, we provided no control group allowing a fair
comparison.
CONCLUSIONS
PTA with selective stenting is a feasible, safe, and
effective procedure for the treatment of iliac occlusive
disease. Initial technical and clinical success rates were high,
and procedural mortality and complication rates were low.
Although the primary patency rates were not high, the
assisted primary and secondary patency rates were excellent.
Careful follow-up can prevent iliac occlusion after PTA and
selective stenting. Overall, 70% of iliac lesions were
treated successfully by angioplasty alone. The results of this
study show that selective stenting offers satisfactory assisted
primary and secondary long-term patency after iliac angio-
plasty.
Risk factor analysis revealed that TASC type C/type D
iliac lesions, stenotic ipsilateral SFA, ulcer/gangrene,
smoking history, and chronic renal failure with hemodialy-
sis were significant independent predictors of adverse long-
term results. Patients with these risk factors should be
followed carefully after endovascular iliac revascularization.
These risk factors could be considered indications for pri-
mary stenting, although further studies are needed to con-
firm this.
We acknowledge Jeffrey A. Gornbein, PhD, and Re-
becca Radbod, MPH, Statistical/Biomathematical Con-
sulting Clinic, Department of Biomathematics, UCLA, for
their statistical expertise and critical comments.
REFERENCES
1. Tetteroo E, van der Graaf Y, Bosch JL, van Engelen AD, Hunink MG,
Eikelboom BC, et al. Randomized comparison of primary stent place-
ment versus angioplasty with selective stent placement in patients with
iliac artery obstructive disease. Dutch Iliac Stent Trial Study Group.
Lancet 1998;351:1153-9.
2. Schneider PA, Andros G. Role of balloon angioplasty and stents in the
management of failed arterial reconstructions. Semin Vasc Surg 1994;
7:178-82.
3. Demasi RJ, Snyder SO,Wheeler JR, Gregory RT, Gayle RG, Parent FN,
et al. Intraoperative iliac artery stents: combination with infra-inguinal
revascularizaion procedures. Am Surg 1994;60:854-9.4. Sapoval MR, Long AL, Pagny JY, Beyssen BM, Raynaud AC, Rostagno
R, et al. Outcome of percutaneous intervention in iliac artery stents.
Radiology 1996;198:481-6.
5. Vorwerk D, Gunther RW, Schurmann K, Wendt G. Aortic and iliac
stenoses: follow-up results of stent placement after insufficient balloon
angioplasty in 118 cases. Radiology 1996;198:45-8.
6. Sarkar R, Ro KM, Obrand DI, Ahn SS. Lower extremity vascular
reconstruction and endovascular surgery without preoperative angiog-
raphy. Am J Surg 1998;176:203-7.
7. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
8. Ahn SS, Rutherford RB, Becker GJ, Comerota AJ, Johnston KW,
McClean GK, et al. Reporting standards for lower extremity arterial
endovascular procedures. Society for Vascular Surgery/International
Society for Cardiovascular Surgery. J Vasc Surg 1993;17:1103-7.
9. Dormandy JA, Rutherford RB. Management of peripheral arterial dis-
ease (PAD). TASC Working Group. TransAtlantic Inter-Society Con-
census (TASC). J Vasc Surg 2000; 31 (suppl):S1-296.
10. Ahn SS, Concepcion B. Indications and results of arterial stents for
occlusive disease. World J Surg 1996;20:644-8.
11. Gunther RW, Vorwerk D, Antonucci F, Beyssen B, Essinger A, Gaux
JC, et al. Iliac artery stenosis or obstruction after unsuccessful balloon
angioplasty: treatment with a self-expandable stent. AJR Am J Roent-
genol 1991;156:389-93.
12. Palmaz JC, Laborde JC, Rivera FJ, Encarnacion CE, Lutz JD,Moss JG.
Stenting of the iliac arteries with the Palmaz stent: experience from a
multicenter trial. Cardiovasc Intervent Radiol 1992;15:291-7.
13. Vorwerk D, Gunther RW. Stent placement in iliac arterial lesions: three
years of clinical experience with the Wallstent. Cardiovasc Intervent
Radiol 1992;15:285-90.
14. Treiman GS, Schneider PA, Lawrence PF, Pevec WC, Bush RL,
Ichikawa L. Does stent placement improve the results of ineffective or
complicated iliac artery angioplasty? J Vasc Surg 1998;28:104-14.
15. Hassen-Khodja R, Sala F, Declemy S, Bouillanne PJ, Batt M, Staccini P.
Value of stent placement during percutaneous transluminal angioplasty
of the iliac arteries. J Cardiovasc Surg 2001;42:369-74.
16. Ballard JL, Sparks SR, Taylor FC, Bergan JJ, Smith DC, Bunt TJ, et al.
Complications of iliac artery stent deployment. J Vasc Surg 1996;24:
545-55.
17. Timaran CH, Stevens SL, Freeman MB, Goldman MH. External iliac
and common iliac artery angioplasty and stenting in men and women. J
Vasc Surg 2001;34:440-6.
18. Murphy KD, Encarnacion CE, Le VA, Palmaz JC. Iliac artery stent
placement with the Palmaz stent: follow-up study. J Vasc Intervent
Radiol 1995;6:321-9.
19. Becquemin JP, Allaire E, Qvarfordt P, Desgranges P, Kobeiter H,
Melliere D. Surgical transluminal iliac angioplasty with selective stent-
ing: long-term results assessed bymeans of duplex scanning. J Vasc Surg
1999;29:422-9.
20. Long AL, Sapoval MR, Beyssen BM, Auguste MC, Le Bras Y, Raynaud
AC, et al. Strecker stent implantation in iliac arteries: patency and
predictive factors for long-term success. Radiology 1995;194:739-44.
21. Johnston KW. Iliac arteries: reanalysis of results of balloon angioplasty.
Radiology 1993;186:207-12.
22. Gardiner G, Meyerovitz M, Stokes K, Clouse M, Harrington D, Bett-
mann M. Complications of transluminal angioplasty. Radiology 1986;
159:201-8.
23. Blum U, Gabelmann A, Redecker M, Noldge G, Dornberg W, Grosser
G, et al. Percutaneous recanalization of iliac artery occlusions: results of
a prospective study. Radiology 1993;189:536-40.
24. Cambria RA, Farooq MM, Mewissen MW, Freischlag JA, Seabrook
GR, Crain MR, et al. Endovascular therapy of iliac arteries: routine
application of intraluminal stents does not improve clinical patency.
Ann Vasc Surg 1999;13:599-605.
25. Palmaz JC, Garcia OJ, Schatz RA, Rees CR, Roeren T, Richter GM, et
al. Placement of balloon-expandable intraluminal stents in iliac arteries:
first 171 procedures. Radiology 1990;174:969-75.
JOURNAL OF VASCULAR SURGERY
September 2005466.e10 Kudo, Chandra, and Ahn26. Wolf YG, Schatz RA, Knowles HJ, Saeed M, Bernstein EF, Dilley RB.
Initial experience with the Palmaz stent for aortoiliac stenoses. AnnVasc
Surg 1993;7:254-61.
27. Bosch JL, Tetteroo E, Mali WP, Hunink MG. Iliac arterial occlusive
disease: cost-effectiveness analysis of stent placement versus percutane-
ous transluminal angioplasty. Dutch Iliac Stent Trial Study Group.
Radiology 1998;208:641-8.
28. Bosch JL, van der Graaf Y, Hunink MG. Health-related quality of
life after angioplasty and stent placement in patients with iliac artery
occlusive disease: results of a randomized controlled clinical trial.
The Dutch Iliac Stent Trial Study Group. Circulation 1999;99:
3155-60.
29. Johnston KW, Rae M, Hogg-Johnston SA, Colapinto RF, Walker PM,
Baird RJ, et al. Five-year results of a prospective study of percutaneous
transluminal angioplasty. Ann Surg 1987;206:403-13.30. Sullivan MT, Childs MB, Bacharach JM, Gray BH, Piedmonte MR.
Percutaneous transluminal angioplasty and primary stenting of the iliac
arteries in 288 patients. J Vasc Surg 1997;25:829-39.
31. Timaran CH, Prault TL, Stevens SL, FreemanMB, GoldmanMH. Iliac
artery stenting versus surgical reconstruction for TASC (TransAtlantic
Inter-Society Consensus) type B and type C iliac lesions. J Vasc Surg
2003;38:272-8.
32. Powell RJ, Fillinger M, BettmannM, Jeffery R, Langdon D, Walsh DB,
et al. The durability of endovascular treatment of multisegment iliac
occlusive disease. J Vasc Surg 2000;31:1178-84.
33. Powell RJ, Fillinger M, Walsh DB, Zwolak R, Cronenwett JL. Predict-
ing outcome of angioplasty and selective stenting of multisegment iliac
artery occlusive disease. J Vasc Surg 2000;32:564-9.Submitted Mar 14, 2005; accepted May 1, 2005.
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 3 Kudo, Chandra, and Ahn 466.e11APPENDIX I, online only.
Univariate primary patency failure rates and failure rate ratios overall and for each of 15 potential predictors (n  151
limbs)
Variable Level N
Primary patency
Months of
follow-up Failures Fail rate* SE Ratio P†
Overall 151 2372 35 1.48 0.25 .2415
Gender Female 47 781 10 1.28 0.40 1.00 .6979
Male 104 1591 25 1.57 0.31 1.23
Age 65 65 1012 18 1.78 0.42 1.00 .2042
65 86 1360 17 1.25 0.30 0.70
Hypertension No 49 843 12 1.42 0.41 1.00 .6973
Yes 102 1529 23 1.50 0.31 1.06
Smoking No 55 1269 10 0.79 0.25 1.00 .0074
Yes 96 1103 25 2.27 0.45 2.88
Coronary artery disease No 58 1012 15 1.48 0.38 1.00 .7561
Yes 93 1360 20 1.47 0.33 0.99
Hyperlipidemia No 65 1136 16 1.41 0.35 1.00 .9468
Yes 86 1236 19 1.54 0.35 1.09
Diabetes mellitus No 78 1058 16 1.51 0.38 1.00 .9369
Yes 73 1314 19 1.45 0.33 0.96
Chronic renal failure with
hemodialysis
No 133 2026 33 1.63 0.28 1.00 .1484
Yes 18 346 2 0.58 0.41 0.35
Indication for PTA Claudication 76 1318 18 1.37 0.32 1.00 .9803
Rest pain 38 577 10 1.73 0.55 1.27
Ulcer/gangrene 37 477 7 1.47 0.55 1.07
Artery treated Both 92 1241 25 2.01 0.40 1.00 .1103
CIA 28 510 5 0.98 0.44 0.49
EIA 31 621 5 0.81 0.36 0.40
TASC classification Type A 39 899 3 0.33 0.19 1.00 .0001
Type B 71 1099 17 1.55 0.38 4.64
Type C/D 41 374 15 4.01 1.04 12.02
Ipsilateral SFA Occluded 41 823 7 0.85 0.32 1.00 .0002
Patent‡ 85 1248 15 1.20 0.31 1.41
Stenosis 25 301 13 4.32 1.20 5.08
Ipsilateral PF Occluded 1 13 0 0.00 0.00 0.3764
Patent¶ 136 2202 30 1.36 0.25 1.00
Stenosis 14 157 5 3.18 1.42 2.34
Selective iliac stenting No 117 1844 26 1.41 0.28 1.00 0.6560
Yes 34 528 9 1.70 0.57 1.21
Concomitant infrainguinal
procedures
No 105 1796 28 1.56 0.29 1.00 0.2415
Yes 46 576 7 1.22 0.46 0.78
PTA, Percutaneous transluminal angioplasty; TASC, TransAtlantic Inter-Society Consensus; CIA, common iliac artery; EIA, external iliac artery; SFA,
superficial femoral artery; PF, profunda femoris artery.
*Failure rates are failures per 100 person-months.
†Kaplan-Meier, log-rank test.
‡Less than 50% stenosis, previously bypassed, or balloon dilated.
¶Less than 50% stenosis or balloon dilated.
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Univariate clinical failure rates and failure rate ratios overall and for each of 15 potential predictors (n  151 limbs)
Variable Level No.
Continued clinical improvement
Months of
follow-up Failures Fail rate* SE Ratio P†
Overall 151 2621 36 1.37 0.23 .4959
Gender Female 47 916 12 1.31 0.38 1.00 .9083
Male 104 1705 24 1.41 0.29 1.07
Age 65 65 1238 14 1.13 0.30 1.00 .2226
65 86 1383 22 1.59 0.34 1.41
Hypertension No 49 1105 12 1.09 0.31 1.00 .1854
Yes 102 1516 24 1.58 0.32 1.46
Smoking No 55 1310 19 1.45 0.33 1.00 .3789
Yes 96 1311 17 1.30 0.31 0.89
Coronary artery disease No 58 1277 13 1.02 0.28 1.00 .1019
Hyperlipidemia No 65 1097 20 1.82 0.41 1.00 .0700
Yes 86 1524 16 1.05 0.26 0.58
Diabetes mellitus No 78 1270 13 1.02 0.28 1.00 .0554
Yes 73 1351 23 1.70 0.35 1.66
Chronic renal failure with
hemodialysis
No 133 2323 28 1.21 0.23 1.00 .0136
Yes 18 298 8 2.68 0.95 2.23
Indication for PTA Claudication 76 1527 10 0.65 0.21 1.00 .0001
Rest pain 38 741 10 1.35 0.43 2.06
Ulcer/gangrene 37 353 16 4.53 1.13 6.92
Artery treated Both 92 1349 24 1.78 0.36 1.00 .1834
CIA 28 721 6 0.83 0.34 0.47
EIA 31 551 6 1.09 0.44 0.61
TASC classification Type A 39 875 9 1.03 0.34 1.00 .2479
Type B 71 1296 17 1.31 0.32 1.28
Type C/D 41 450 10 2.22 0.70 2.16
Ipsilateral SFA Occluded 41 866 9 1.04 0.35 1.00 .0339
Patent‡ 85 1295 15 1.16 0.30 1.11
Stenosis 25 460 12 2.61 0.75 2.51
Ipsilateral PF Occluded 1 13 0 0.00 0.00 .3907
Patent¶ 136 2393 31 1.30 0.23 1.00
Stenosis 14 215 5 2.33 1.04 1.80
Selective iliac stenting No 117 1974 29 1.47 0.27 1.00 .7014
Yes 34 647 7 1.08 0.41 0.74
Concomitant infrainguinal
procedures
No 105 2039 26 1.28 0.25 1.00 .5484
Yes 46 582 10 1.72 0.54 1.35
PTA, Percutaneous transluminal angioplasty, TASC, TransAtlantic Inter-Society Consensus; CIA, common iliac artery; EIA, external iliac artery; SFA,
superficial femoral artery; PF, profunda femoris artery.
*Failure rates are failures per 100 person-months.
†Kaplan-Meier, log-rank test.
‡50% stenosis, previously bypassed, or balloon dilated.
¶50% stenosis or balloon dilated.
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Univariate limb salvage rates and failure rate ratios overall and for each of 15 potential predictors (n  151 limbs)
Variable Level No.
Limb salvage
Months of
follow-up Failures Fail rate* SE Ratio P†
Overall 151 3089 6 0.194 0.08
Gender Female 47 1062 3 0.282 0.16 1.00 0.2782
Male 104 2027 3 0.148 0.09 0.52
Age 65 65 1416 3 0.212 0.12 1.00 0.6664
65 86 1673 3 0.179 0.10 0.85
Hypertension No 49 1241 2 0.161 0.11 1.00 0.8882
Yes 102 1848 4 0.216 0.11 1.34
Smoking No 55 1593 2 0.126 0.09 1.00 0.6083
Yes 96 1496 4 0.267 0.13 2.13
Coronary artery disease No 58 1454 2 0.138 0.10 1.00 0.7646
Yes 93 1635 4 0.245 0.12 1.78
Hyperlipidemia No 65 1366 4 0.293 0.15 1.00 0.2680
Yes 86 1723 2 0.116 0.08 0.40
Diabetes mellitus No 78 1465 2 0.137 0.10 1.00 0.4821
Yes 73 1624 4 0.246 0.12 1.80
Chronic renal failure with
hemodialysis
No 133 2726 5 0.183 0.08 1.00 0.7947
Yes 18 363 1 0.275 0.28 1.50
Indication for PTA Claudication 76 1741 0 0.000 0.00 0.0097
Rest pain 38 851 2 0.235 0.17 1.00
Ulcer/gangrene 37 497 4 0.805 0.40 3.42
Artery treated Both 92 1646 4 0.243 0.12 1.00 0.9294
CIA 28 744 1 0.134 0.13 0.55
EIA 31 699 1 0.143 0.14 0.59
TASC classification Type A 39 1028 2 0.195 0.14 1.00 0.2390
Type B 71 1560 1 0.064 0.06 0.33
Type C/D 41 501 3 0.599 0.35 3.08
Ipsilateral SFA Occluded 41 1083 0 0.000 0.0679
Patent‡ 85 1446 6 0.415 0.17
Stenosis 25 560 0 0.000
Ipsilateral PF Occluded 1 13 0 0.000 0.00 0.8272
Patent¶ 136 2799 5 0.179 0.08 1.00
Stenosis 14 277 1 0.361 0.36 2.02
Selective iliac stenting No 117 2399 6 0.250 0.10 1.00 0.1649
Yes 34 690 0 0.000 0.00
Concomitant infrainguinal
procedures
No 105 2476 2 0.081 0.06 1.00 0.0261
Yes 46 613 4 0.653 0.33 8.08
PTA, Percutaneous transluminal angioplasty, TASC, TransAtlantic Inter-Society Consensus; CIA, common iliac artery; EIA, external iliac artery; SFA,
superficial femoral artery; PF, profunda femoris artery.
*Failure rates are failures per 100 person-months.
†Kaplan-Meier, log-rank test.
‡50% stenosis, previously bypassed, or balloon dilated.
¶50% stenosis or balloon dilated.
